Our platform integrates generative or predictive AI capabilities with extensive human knowledge in biologics drug design and continuously improves its performance based on a large proprietary database.
PLATFORM
Best-in-class biologics
discovery platform
- 01 OVERVIEW
Our platform enables rapid design and optimization of potential best-in-class biologics to transform the treatment landscape for a broad spectrum of human diseases.
With substantial crowding around a limited set of biological mechanisms, there is an unprecedented need to generate best-in-class candidates with transformative differentiation. However, conventional computational and wet-lab workflows continue to fall short in delivering the necessary quality, speed, and consistency.
Ailux has built an end-to-end discovery platform that delivers high-quality therapeutic candidates. Leveraging novel modality design, our platform unlocks multi-parametric exploration of best-in-class profiles without compromise, setting a new standard for advanced biologics discovery.
- 02 DIFFERENTIATION
Unique approach for best-in-class design
Unparalleled intelligence integration
Thorough platform validation
We diligently de-risk our platform in wholly-owned internal projects and consistently benchmark its performance head-to-head with traditional approaches.
Turning innovation into practical impact
Our platform has the proven ability to tackle complex and challenging problems, including multi-objective discovery, next-gen engineering, and advanced modalities, which in turn spurs further rounds of innovation.
- 03 APPLICATION
How do we create unique value with AI?
Hard Targets
- Multipass transmembrane proteins
- Epitope-focused antigen design
- Rare hit identification
Advanced Engineering
- Developability de-risking
- pH-sensitivity engineering
- Species cross-reactivity engineering
- Affinity/specificity modulation
Multispecifics Design
- Difficult scFv engineering
- Common light chain engineering
- Bispecific optimization
- 04 ENGINE
Industry-leading AI/ML models for advanced drug design
Protein complex structure prediction
- Bridging the 1D and 3D protein space through deep learning
- Unraveling antibody-antigen interaction with high accuracy at scale
- Unlocking novel downstream applications
Generative AI design for protein-based therapeutics
- Proprietary generative LLM for proteins
- Generates highly-developable protein/antibody sequence
- Conditional generation to the desired profile
Predictive AI suite for multi-parametric evaluation
- Comprehensive computational suite dedicated to biologics
- Pre-trained on a proprietary database significantly larger than what’s publicly available
- Harnesses the power of active learning to refine project-specific models
- 05 DATABASE
AtlaX™ Database
Proprietary multi‑modal
biologics database
biologics database
- Curated through specialized high-throughput techniques
- Carefully balanced with negative results
- Boosting model performance with the scaling law
Data highlights
5x
More heavy & light-chain paired Ab sequences than OAS
90K +
Unique Ab-Ag sequence pairs (in-house or from patents)
15K +
Ab-Ag binding affinity data (SPR, BLI, or ELISA)
2K +
Epitope data for specific Ag-Ab sequence pairs
4.5x
More loop-mediated complex structures than SAbDab
10x
Developability data compared to the literature
Data as of August 31, 2025
- 06 PARTNERING
Innovate together to build transformative medicines.
